We previously reported that reduced intensity conditioning (RIC) regimen with fludarabine, BU and 2.5 mg/kg of rabbit anti-thymocyte globulin (r-ATG) was effective but associated with a high rate of acute and chronic GVHD. Therefore, we increased the dose of r-ATG to 5 mg/kg. In this report, we analyzed 87 patients with AML or myelodysplastic syndrome (MDS) undergoing allo-SCT from an HLA-identical sibling donor from 2000 to 2010. RIC consisted of fludarabine, BU and r-ATG 2.5 mg/kg on 1 day (r-ATG1; n ¼ 53) or 2.5 mg/kg per day over 2 days (r-ATG2; n ¼ 22). Grade 2 -4 acute GVHD incidence at day 100 was 30.2% and 8.8% in the r-ATG1 and r-ATG2 groups, respectively (P ¼ 0.038). Extensive chronic GVHD incidence was 60.4% and 12% in the r-ATG1 and r-ATG2 groups, respectively (Po0.001). The relapse incidences (RI) at 24 months were 18.9% and 28.5% in r-ATG1 and r-ATG2 groups, respectively (P ¼ 0.640). Overall and PFS were not different between the r-ATG1 and r-ATG2 groups. r-ATG dose at 5 mg/kg in the setting of RIC seems a good balance allowing GVHD prevention and antitumor effect with a remarkable reduction of GVHD incidence without an identical level of increased relapse rate.
Introduction
The use of allo-SCT with standard conditioning has been associated with better disease control as compared with standard chemotherapy for high-risk AML.
1,2 However, most leukemic or myelodysplastic patients are diagnosed after the sixth decade of life. In elderly patients, standard myeloablative conditioning regimens are usually associated with a high rate of transplantation-related deaths, limiting the use of this procedure. 3 -5 Younger patients with severe comorbidities are similarly contraindicated for this standard approach. Reduced intensity conditioning (RIC) regimens have allowed the extension of allo-SCT to patients not eligible for myeloablative conditioning, with lower regimenrelated toxicity and non-relapse mortality (NRM). 6 -8 Allogeneic antileukemic effect has been regularly documented in this situation. Altogether, this explains why RIC-based allo-SCT is regularly considered for AML patients even in first remission if HLA-identical sibling donor is identified. 9 Several types of RIC regimens have already been evaluated but the optimal balance between disease control and toxicity still needs to be found. 10 -12 For more than a decade we have used a fludarabine-BU-rabbit anti-thymocyte globulin (r-ATG) (FBA)-based regimen 13 in which we have modified, over the years, stem cell source, 14 r-ATG dose 15 and BU formulation in different situations. 16 -19 Overall, we found this combination to be adaptable with encouraging initial results. 17, 20, 21 We recently reported that despite an interesting overall and disease-free survival benefit, the use of this regimen with 2.5 mg/kg of r-ATG was associated with high incidences of grade 2-4 acute (43%) and extensive chronic (70%) GVHD. 13 This was associated with a 14% GVHDrelated death probability and an impaired quality of life owing to long-lasting extensive chronic GVHD. Consequently, we increased the r-ATG dose from 2.5 mg/kg on 1 day to 5 mg/kg over 2 days aiming to decrease GVHD incidence and severity. In this study, we analyzed the outcome of patients treated for myeloid malignancies with an FBA-RIC including 2.5 mg/kg or 5 mg/kg of r-ATG in preparation of an HLA-identical sibling transplantation. Patients with one of the following criteria were eligible for a RIC strategy: age450 years, previous auto-SCT and recent severe infection or presence of comorbidity. Supportive care was administered as previously reported. 13 
Patients and methods

This is
Disease risk evaluation
In assessing the impact of transplant on relapse rate after transplant, we categorized patients upon their risk of relapse. Patients with AML were defined as high risk of relapse by the presence of one of the following criteria: (1) adverse cytogenetic group (inv(3), t(3;3), t(6;9), 11q23 rearrangement except t(9;11), À5 or del(5q), 17p abnormalities, À7, complex karyotype); (2) AML with myelodysplasia-related changes according to WHO (World Health Organization) classification; 22 (3) therapy-related AML according to WHO classification and (4) no CR at the time of transplantation according to Cheson response criteria. 23 MDS was considered at high risk according to the International Prognostic Scoring System score at diagnosis (intermediate-2 and high risk) or if MDS was chemo/radiotherapy-induced. 24 Other patients were considered at standard risk of relapse.
Statistical analysis
Survival outcomes were defined from the date of transplantation. Death from any cause was relevant event for overall survival (OS). Events for PFS were relapse or death from any cause. In an attempt to qualitatively assess patients outcome, we analyzed patients survival without the occurrence of relapse or extensive chronic GVHD using relapse, occurrence of extensive chronic GVHD or death (from any cause) as relevant event, with censored cases defined as patients without event at last contact. As deaths without evidence of progression for relapse incidence (RI), deaths following disease progression were treated as competing events 25 in NRM analyses. For OS, PFS and survival without relapse or extensive chronic GVHD occurrence, Kaplan-Meier method 26 and log-rank test were used for estimations and univariate analysis. For RI and NRM, Prentice estimation and Gray test were used. HRs were estimated with a 95% confidence interval (CI). To investigate their impact on survival outcomes, acute GVHD and chronic GVHD were treated as time-dependant covariables. All survival analyses were computed on the R 2.13.1 statistical software (http:// www.R-project.org).
Acute and chronic GVHD were classified as elsewhere reported. 27, 28 Univariate analyses were performed using Cox regression. 29 
Results
Patient characteristics
A total of 87 consecutive patients fitting the eligibility criteria of the study were included in this analysis. In all, 75 patients had AML and 12 MDS. They all received an FBAbased RIC before transplantation with PBSC from HLAidentical sibling donor. Patient characteristics are summarized in Table 1 . Median age was 52 years . RIC was performed in 40 patients o50 years because of a previous auto-SCT (n ¼ 16), a comorbidity including severe cardiac, hepatic, respiratory or renal dysfunction (n ¼ 9), a previous severe infection (severe invasive aspergillosis or multiple septicemia with multiresistant bacteria) (n ¼ 7) or a poor prognosis feature (n ¼ 8). A total of 53 patients received 2.5 mg/kg of r-ATG over 1 day (r-ATG1) and 34 patients 5 mg/kg over 2 days (r-ATG2). The two cohorts were statistically different for age, transplantation period, BU formulation, post-GVHD prophylaxis and follow-up (Table 1 ).
Acute and chronic GVHD incidence analysis
For all 87 patients, grade 2 -4 and grade 3 -4 acute GVHD incidences were 21.8%, (95% CI: (13.1 -30.6)) and 11.5% (95% CI: (4.7 -18.2)), repectively. Median time to grade 2 -4 acute GVHD was 41 days (11 -124). Grade 2 -4 acute GVHD incidence at day 100 was significantly reduced from 30.2% to 8.8% in the r-ATG1 and r-ATG2 groups, respectively (P ¼ 0.038) ( Table 2 and Figure 1a ). There was no significant difference in grade 3 -4 acute GVHD between r-ATG1 and r-ATG2 groups. For the whole cohort of patients, overall and extensive chronic GVHD incidence was 51.2% (95% CI: (40.5 -61.9)) and 41.9% (95% CI: (31.3 -52.4)), respectively. Median time to chronic GVHD was 4.3 months (2.9 -36.9). Extensive chronic GVHD incidence was significantly reduced from 60.4% to 12% in the r-ATG1 and r-ATG2 groups, respectively (Po0.001) ( Table 2 and Figure 1b) . In r-ATG1 patients, CsA or CsA plus mycophenolate mofetil as Increased r-ATG dose reduces GVHDGVHD prophylaxis did not influence cumulative incidence of acute (P ¼ 0.23) and chronic (P ¼ 0.19) GVHD.
NRM rate analysis
The global NRM probability was 18% and 20.8% at 1 and 5 years, respectively. Transplant-related deaths occurred at a median time of 9.2 months (0.7 -87.8). Grade 2 -4 acute GVHD was adversely associated with NRM (HR ¼ 4.1 (1.8 -9.5); Po0.001). There was no difference between the two r-ATG dose groups with a 1-year (day 100) NRM of 17% (3.8%) and 19.6% (5.9%) for r-ATG1 and r-ATG2, respectively (P ¼ 0.560) ( Table 2 ). Regarding the causes of NRM, GVHD-related deaths concerned 11 of 13 r-ATG1 patients (84%) and 4 of 7 r-ATG2 patients (57%) who died from non relapse causes (P ¼ 0.207). Four patients died from pneumonia and one from severe cardiac dysfunction.
RI analysis
The RI at 24 months was 21.7% with a median time to relapse of 4.9 months (1 -39). Relapses occurred in the first 2 years for 18 of the 21 relapsed patients. Three patients relapse later, at 25, 26 and 39 months. No statistical difference was found regarding r-ATG dose, with a 2-year RI at 18.9% and 28.5%, respectively, in r-ATG1 and r-ATG2 groups (P ¼ 0.640) ( Table 2 and Survival analyses OS probability at 2 and 5 years were 63.1% and 58.1%, respectively. For the r-ATG1 and r-ATG2 groups, 2 year (5 year) OS were 65.8% (CI95, 54.2 -80) (59.8% (CI95, 47.8 -74.7)) and 59.2% (CI95, 43.3 -80.9) (59.2% (CI95, 43.3 -80.9)), respectively (P ¼ 0.550) ( Table 2 and Figure 3a ). Factors associated with adverse OS were high-risk diseases (HR ¼ 2.5 (1.3 -4.8) P ¼ 0.005) and grade 2 -4 acute GVHD (HR ¼ 2.9 (1.5 -5.6) P ¼ 0.001). For the whole cohort, 2-and 5-year PFS were 58.9% and 53.2%, respectively. No statistical difference was found regarding r-ATG dose, with a 2-year (5-year) PFS at 64.2% (56.6%) and 47.4% (47.4%) (P ¼ 0.386) ( Table 2 and Figure 3b ).
In the whole cohort, 2-year survival without relapse or extensive chronic GVHD was 25.9%. Increased r-ATG dose significantly improved this outcome from 17% to 37.9% for r-ATG1 and r-ATG2 groups, respectively (P ¼ 0.002) ( Table 2 and Figure 4) .
Discussion
Since 1998, we decided upfront to include r-ATG in our RIC approach for all clinical situations in order to limit Table 2 Outcome of the r-ATG1 and r-ATG2 groups r-ATG1 (n ¼ 53) Abbreviations: HR ¼ hazard ratio; OS ¼ overall survival; r-ATG ¼ rabbit anti-thymocyte globulin; RI ¼ relapse incidence. the transplant-related toxicity. We initially used a high 7.5 -10 mg/kg dosage and have been faced with poor disease control 14, 15 and high rates of infection. 30 We recently reported a long-term experience with low (2.5 mg/kg) dose of r-ATG; although patient outcome was promising we decided in 2008 to consider an intermediate 5 mg/kg dose because of an unacceptable rate of extensive chronic GVHD. 13 We considered the introduction of MTX in post-graft immunosuppressive treatment could be an efficient way to decrease GVHD incidence. However, we elicited to rather increase the dose of r-ATG in order to limit adverse side effects as mucositis or cytokine release. In the present report, we compared the impact of these two latter r-ATG doses in patients with AML or MDS, receiving transplantation from a matchedrelated donor after a RIC regimen. Because over time, along with the modification of r-ATG dose, we also changed some aspects of our practice, this retrospective Increased r-ATG dose reduces GVHDstudy includes some other differences in characteristics between the two groups. Overall, in the r-ATG1 group, age was younger and post-graft GHVD prophylaxis more intense in some patients. Both factors may have contributed to a lower risk of GVHD and NRM. Even accounting for this, our results suggest that increased r-ATG-dose in FBA-based RIC reduces both acute grade 2 -4 GVHD from 30.2% to 8.8% (P ¼ 0.038) and extensive chronic GVHD incidence from 60.4% to 12% (Po0.001) ( Figures  1a and b) . Time periods of transplantation were different between the groups. This represents a potential bias in our study because a significantly shorter median follow up at 23 months in r-ATG2 group (r-ATG1: 69 months). However, regarding the dramatic decrease of acute and chronic GVHD incidences in r-ATG2, it is likely that the effect on GVHD is more attributable to r-ATG dose than to timing. It should be also noted that BU formulation was mainly oral in r-ATG1 group and only i.v. in r-ATG2 group. This may influence GVHD incidence in a part, but evaluation of such different exposure is still needed. Duggan et al. 31 have also reported intermediate r-ATG dose (4.5 mg/kg) in FBA-based RIC. Grade 2 -4 acute and chronic GVHD incidences were 19% and 44%, respectively. Compared with our results with 5 mg/kg of r-ATG dose, this higher incidence of GVHD could be explained by the use of matched unrelated donor in their series.
r-ATG represents an in-vivo form of T-cell depletion and its impact on GVHD prophylaxis has been extensively documented. 32 -34 However, despite the GVHD reduction, NRM was not decreased in our series. Although population size could be a limitation, it should be quoted that age was 10 year older in r-ATG2 group, representing a plausible explanation. It should be also noted that chronic GVHD was more effectively reduced than acute GVHD, a major cause of NRM. Despite the favorable impact on GVHD incidence, the use of increased r-ATG dose need to be discussed regarding other adverse side effect as infectious disease. A recent study reported that the use of r-ATG in RIC is a strongly predictive factor of EBV reactivation. 35 However, outcome was not influenced by the use of r-ATG.
Preemptive treatment by rituximab explains in part this favorable outcome and the low lymphoproliferative disease incidence despite the use of r-ATG.
RI was not statistically increased in r-ATG2 group. The small population numbers may account for this statistical result. With a shorter median follow-up in r-ATG2 group (23 months), long-term evaluation is still needed to confirm the RI in this group. However, median time to relapse was 4.9 months and relapses occurred in the first 2 years after transplantation for all but three patients. Considering these data, a further dramatic increase of relapse is unlikely to occur with a longer follow-up. High doses of r-ATG have been documented to be associated with loss of tumor control.
14,15 Although we do recognize that it is likely that any dose will have an impact on disease control, our data seem to suggest that increasing r-ATG from a low (2.5 mg/ kg) to an intermediate (5 mg/kg) dose in the setting of RIC may allow much higher GVHD prevention, without a loss of the same degree of antitumor control. 31 The absence of a statistical difference in relapse rate between the two groups should not occult the fact that relapse occurrence remains a concern and needs further consideration anyway.
Beyond NRM, allogeneic transplantation is a procedure sometimes associated with highly deleterious toxicities, notably when patients present with severe chronic GVHD. Indeed in some patients, surviving disease free may result in an extremely poor quality of life related to these symptoms. Without prospective evaluation, the quality of life is usually neglected. In order to address this and by analogy with the TWiST methodology evaluation (time without symptom and toxicity), 36 we developed a simple composite outcome end point where death, relapse, but also occurrence of extensive chronic GVHD were considered as relevant events. The increased r-ATG-dose dramatically improved this end point (Figure 4 ). Although not a standardized evaluation, we feel this type of information may be worthwhile when comparing treatments with identical survival.
Finally, patients with high-risk disease continue to experience poor outcomes after RIC allo-SCT. High-risk diseases had a significantly adverse influence on RI (HR ¼ 2.75 (1.15 -6.58) P ¼ 0.021) and OS (HR ¼ 2.5 (1.3 -4.8) P ¼ 0.005). This has already been shown in previous retrospective studies. 37 Further developments of more intensive but low toxicity regimens might represent an opportunity. 38 Also after graft treatment using prophylactic DLI and/or targeted therapy may be another investigational direction. 39, 40 In conclusion, a dose of 5 mg/kg of r-ATG reduced dramatically both acute and chronic GVHD incidence as compared with a dose of 2.5 mg/kg, without a significant increase of relapse rate when associated to fludarabine and BU in the situation of HLA-identical sibling transplant. The low incidence of extensive chronic GVHD suggests an improvement of quality of life and a lower long-term morbidity rate. Despite the limitations of this report because of its retrospective nature, these results are in line with previous reports and promising. 15, 41 They indicate this precise regimen may offer an interesting platform to develop further strategy, aiming to better control disease while retaining a low toxicity. Increased r-ATG dose reduces GVHD
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